Conference Abstracts : [6734]
Collection home page

Abstracts for conference papers, posters, or presentations.

Browse
in this collection
Subscribe to this collection to receive daily e-mail notification of new additions RSS Feed RSS Feed RSS Feed
Collection's Items (Sorted by Submit Date in Descending order): 141 to 160 of 6734
< previous   next >
PreviewIssue DateTitleAuthor(s)
20-Feb-2026On the clock: Time implications for pharmacist assessors for medical intern prescribing entrustable professional activities.Shepherd S.; Jovanovic M.; Raghunath S.; Johnson C. ; Wood S. 
20-Feb-2026Unravelling laboratory results: A dynamic, interactive pharmacy workshop across multiple sites.Solanki J.; Rattle A.; Ha J.; Clark M.; Pinto A.; Gibson S.; Pho C.; Guo S.M.; Wood S. 
20-Feb-2026Bevacizumab use in Australian patients with epithelial ovarian cancer: A real-world study survival analysis.Shivasabesan G.; Phung J.; Francis K.; Knights T.; Perera S.; Wan K.M.; Rome R.M.; Zalcberg J.R.; Friedlander M.L.; Lee Y.C.
20-Feb-2026MK-1084 for KRAS G12C-mutated advanced colorectal cancer (CRC): Updated findings from KANDLELIT-001.Xue J.; Lugowska I.; Simonelli M.; Sacher A.G.; Stathis A.; Dziadziuszko R.; Park J.O.; Moreno Garcia V.; Yeh Y.-M.; Sendur M.A.N.; Su Y.-L.; Caglevic C.; Xu R.-H.; Perets R.; Ahern E.S.; Pal A.; Jemielita T.; Molife R.L.; Choi S.Y.; Rojas C.I.
20-Feb-2026Cultivating a sustainable approach to practitioner wellbeing.Booth J.; Ewing W.; Kirsa S. 
20-Feb-2026Cancer admission pattern and outcomes among culturally and linguistically diverse (CALD) migrant population: An Australian retrospective single-centre study.Chow K.
20-Feb-2026De novo and acquired MET amplification in patients (pts) with non-small cell lung cancer (NSCLC) treated with tepotinib: Results from a real-world data analysis in Australia.Arulananda S.; Markman B.; Clay T.D.; Parakh S. ; Jennens R.; Peters G.D.; Gasking S.; Itchins M.
20-Feb-2026Purple Pen Podcast - Podcasting: A novel medium of continuing education for pharmacy professionals.Xenos K.; Booth J.; Tasker N.
20-Feb-2026Bringing andragogy and constructivism to administration and leadership training: An innovative approach to training tomorrow's pharmacy administrators and leaders.Morbitzer K.; Stepanovic M.; Eckel S.; Kirsa S. ; Galbraith K.
20-Feb-2026Real-world outcomes in limited-stage SCLC: A 10-year retrospective analysis.Mahera M.; Kwok A.; Paul E.; Tan M.Y.; Alamgeer M. ; Wheeler G.; Arulananda S.
21-Feb-2026Alterations in pathways of complement and platelet signalling are evident following proteome profiling of plasma from patients with Vaccine Induced Immune Thrombotic Thrombocytopenia (VITT).Keragala C.B.; Emery-Corbin S.J.; Olechnowicz S.W.Z.; Yousef J.; Bowden R.; Attard C.; Dagley L.F.; Medcalf R.L.; Monagle P.; Chunilal S. ; Tran H. ; McFadyen J.; Stevens H.; Ho H.
24-Feb-2026Comparison of average Water Equivalent Diameter values between CTContour and vendor specific calculations in CT dosimetry.Payne S.; Badawy M. 
24-Feb-2026Safety and efficacy of obicetrapib in patients at high cardiovascular risk.Nicholls S.J. ; Nelson A.J.; Ditmarsch M.; Kastelein J.J.P.; Ballantyne C.M.; Ray K.K.; Navar A.M.; Nissen S.E.; Harada-Shiba M.; Hsieh A.
24-Feb-2026Effect of obicetrapib on new onset diabetes in patients with elevated LDL-C receiving maximally tolerated statin therapy: pooled analyses of the BROADWAY and BROOKLYN trials.Ray K.K.; Szarek M.; Navar A.M.; Nelson A.J.; Ballantyne C.M.; Kling D.; Ditmarsch M.; Davidson M.H.; Kastelein J.J.P.; Nicholls S.J. 
24-Feb-2026Impact of obicetrapib on major adverse cardiovascular events: a pooled analysis of phase 3 clinical trials.Nicholls S.J. ; Nelson A.J.; Ray K.K.; Ditmarsch M.; Kling D.; Hsieh A.; Szarek M.; Kastelein J.J.P.; Davidson M.H.
24-Feb-2026Impact of cholesteryl ester transfer protein inhibitor, obicetrapib, on lipoprotein(a) levels: pooled data from phase iii clinical trials.Nicholls S.J. ; Ray K.K.; Szarek M.; Ditmarsch M.; Kling D.; Hsieh A.; Nelson A.J.; Davidsond M.H.; Kasteleind J.J.P.
24-Feb-2026Food-specific CD4+ FOXP3+ regulatory t cells identify delayed-hypersensitivity allergies and food triggers in pediatric patients.Poloni C.; Sze A.; Nguyen J.; Giles E. ; Steiner T.; Cook L.
24-Feb-2026Impact of obicetrapib on major adverse cardiovascular events: a pooled analysis of phase 3 clinical trials.Nicholls S.J. ; Nelson A.J.; Ray K.K.; Ditmarsch M.; Kling D.; Hsieh A.; Szarek M.; Kastelein J.J.P.; Davidson M.H.
24-Feb-2026Comparison of average Water Equivalent Diameter values between CTContour and vendor specific calculations in CT dosimetry.Payne S.; Badawy M. 
24-Feb-2026Effect of obicetrapib on new onset diabetes in patients with elevated LDL-C receiving maximally tolerated statin therapy: pooled analyses of the BROADWAY and BROOKLYN trials.Ray K.K.; Szarek M.; Navar A.M.; Nelson A.J.; Ballantyne C.M.; Kling D.; Ditmarsch M.; Davidson M.H.; Kastelein J.J.P.; Nicholls S.J. 
Collection's Items (Sorted by Submit Date in Descending order): 141 to 160 of 6734
< previous   next >

Date issued